$641 Million is the total value of ORACLE INVESTMENT MANAGEMENT INC's 21 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 58.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TSRO | Sell | TESARO INC | $157,174,000 | -6.4% | 1,021,475 | -18.2% | 24.50% | -12.0% |
| AXDX | New | ACCELERATE DIAGNOSTICS INC | $114,213,000 | – | 4,719,526 | +100.0% | 17.81% | – |
| MZOR | Sell | MAZOR ROBOTICS LTDsponsored ads | $80,732,000 | +35.4% | 2,711,842 | -0.3% | 12.59% | +27.3% |
| NXTM | Buy | NXSTAGE MEDICAL INC | $73,029,000 | +2.4% | 2,721,906 | +0.0% | 11.38% | -3.8% |
| QDEL | QUIDEL CORP | $56,997,000 | +5.7% | 2,517,554 | 0.0% | 8.89% | -0.6% | |
| PACB | Sell | PACIFIC BIOSCIENCES CALIF IN | $28,470,000 | +35.8% | 5,506,732 | -0.2% | 4.44% | +27.7% |
| OPK | Sell | OPKO HEALTH INC | $28,264,000 | -14.0% | 3,533,000 | -0.0% | 4.41% | -19.2% |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $21,524,000 | -11.9% | 6,726,147 | -15.2% | 3.36% | -17.2% |
| BIOL | BIOLASE INC | $19,740,000 | -3.6% | 14,622,050 | 0.0% | 3.08% | -9.3% | |
| VRML | Buy | VERMILLION INC | $19,316,000 | +135.8% | 9,241,956 | +7.2% | 3.01% | +121.6% |
| XON | Sell | INTREXON CORP | $13,773,000 | -30.9% | 694,902 | -15.3% | 2.15% | -35.1% |
| EPZM | New | EPIZYME INC | $8,866,000 | – | 516,940 | +100.0% | 1.38% | – |
| ARAY | Sell | ACCURAY INC | $6,736,000 | -1.8% | 1,418,194 | -4.9% | 1.05% | -7.7% |
| AGEN | New | AGENUS INC | $6,444,000 | – | 1,709,379 | +100.0% | 1.00% | – |
| CFRX | CONTRAFECT CORP | $2,128,000 | +2.9% | 1,182,032 | 0.0% | 0.33% | -3.2% | |
| BIIB | Sell | BIOGEN INC | $1,741,000 | -8.7% | 6,368 | -5.3% | 0.27% | -14.2% |
| TSRO | New | TESARO INCcall | $1,585,000 | – | 350,000 | +100.0% | 0.25% | – |
| AXDX | New | ACCELERATE DIAGNOSTICS INCcall | $475,000 | – | 100,000 | +100.0% | 0.07% | – |
| AQB | New | AQUABOUNTY TECHNOLOGIES INC | $135,000 | – | 12,204 | +100.0% | 0.02% | – |
| EYES | SECOND SIGHT MED PRODS INC | $61,000 | -39.0% | 50,804 | 0.0% | 0.01% | -41.2% | |
| NXTM | New | NXSTAGE MEDICAL INCcall | $20,000 | – | 100,000 | +100.0% | 0.00% | – |
| ZIOP | Exit | ZIOPHARM ONCOLOGY INC | $0 | – | -6,661 | -100.0% | -0.01% | – |
| AGEN | Exit | AGENUS INC | $0 | – | -1,925,918 | -100.0% | -1.32% | – |
| AXK | Exit | ACCELERATE DIAGNOSTICS INC | $0 | – | -5,032,389 | -100.0% | -17.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| OPKO HEALTH INC | 42 | Q3 2023 | 10.6% |
| PACIFIC BIOSCIENCES CALIF IN | 42 | Q3 2023 | 22.6% |
| BIOGEN INC | 42 | Q3 2023 | 0.6% |
| QUIDEL CORP | 36 | Q1 2022 | 52.5% |
| AMARIN CORP PLC | 31 | Q3 2021 | 23.1% |
| VERMILLION INC | 28 | Q1 2020 | 3.8% |
| AGENUS INC | 25 | Q3 2023 | 9.8% |
| TESARO INC | 23 | Q4 2018 | 27.8% |
| ACCELERATE DIAGNOSTICS INC | 23 | Q2 2023 | 23.0% |
| MAZOR ROBOTICS LTD | 20 | Q1 2018 | 18.0% |
View ORACLE INVESTMENT MANAGEMENT INC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View ORACLE INVESTMENT MANAGEMENT INC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.